ASCO 2025 | The current state of cervical cancer management in 2025
Ritu Salani, MD, MBA, University of California Los Angeles, Los Angeles, CA, comments on the evolving landscape of cervical cancer treatment, noting that immunotherapy has expanded from second-line to frontline use, including in locally advanced cervical cancer. However, there is still a need for more effective treatments, where tisotumab vedotin, an antibody-drug conjugate (ADC) targeting tissue factor, provides limited responses. Novel ADCs such as sacituzumab govitecan, which targeted TROP2, are being assessed. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so the landscape for cervical cancer treatment has really changed over the last couple of years with the introduction of immunotherapy and checkpoint inhibitors. We were first using this in second-line setting or kind of the recurrent setting, but because of such advances, it moved to the frontline with advanced and recurrent chemotherapy. And now it’s even moved into those patients with locally advanced cervical cancer, so receiving chemoradiation...
Yeah, so the landscape for cervical cancer treatment has really changed over the last couple of years with the introduction of immunotherapy and checkpoint inhibitors. We were first using this in second-line setting or kind of the recurrent setting, but because of such advances, it moved to the frontline with advanced and recurrent chemotherapy. And now it’s even moved into those patients with locally advanced cervical cancer, so receiving chemoradiation. So at some point, most patients with cervical cancer should be exposed to immunotherapy. And since we were originally using this as second line or beyond, we now have this huge needs gap in that area. There are drugs that are starting to fill that space. Tisotumab vedotin is one of those agents, and that’s an antibody drug conjugate, which is targeting tissue factor, which is widely expressed in cervical cancer. It’s an exciting target. The drug is a wonderful drug and it provides some objective response rates and survival benefits for patients, but they’re modest at best and they come at the expense of toxicities. And so we’re looking at ways to maybe capitalize on this opportunity to provide our patients better treatments that may be more effective, ideally, with longer survival and less toxicity. And that’s where our target or our study of TROP2 antibody drug conjugate called sacituzumab govitecan comes in.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
